Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: Implications for early cardiac remodeling

Circulation

Volumn 128, Issue 11, 2013, Pages 1225-1233

  Coelho Filho, Otavio R ^a,b   Shah, Ravi V ^a   Mitchell, Richard ^a,b   Neilan, Tomas G ^a   Moreno, Heitor ^a   Simonson, Bridget ^c   Kwong, Raymond ^a   Rosenzweig, Anthony ^c   Das, Saumya ^c   Jerosch Herold, Michael ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; N(G) NITROARGININE METHYL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CARDIOMYOCYTE HYPERTROPHY; CARDIOVASCULAR MAGNETIC RESONANCE; CELL SIZE; CELL VOLUME; CONTROLLED STUDY; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE OVERLOAD; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL;

HYPERTROPHY; MAGNETIC RESONANCE IMAGING;

ALGORITHMS; ANIMALS; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; BODY WATER; CARDIOMYOPATHY, HYPERTROPHIC; CELL SIZE; CONTRAST MEDIA; GADOLINIUM DTPA; HYPERTENSION; HYPERTROPHY; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MICE; MYOCYTES, CARDIAC; NG-NITROARGININE METHYL ESTER; PHENOTYPE; RANDOM ALLOCATION; VENTRICULAR REMODELING;

EID: 84884349322     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.000438     Document Type: Article

References (50)

1. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568-575
2. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327-334
3. Devereux RB, Dahlof B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol. 1996;78:61-65
4. Dweck MR, Joshi S, Murigu T, Gulati A, Alpendurada F, Jabbour A,Maceira A, Roussin I, Northridge DB, Kilner PJ, Cook SA, Boon NA,Pepper J, Mohiaddin RH, Newby DE, Pennell DJ, Prasad SK. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: Insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:50
5. Sharma S, Maron BJ, Whyte G, Firoozi S, Elliott PM, McKenna WJ. Physiologic limits of left ventricular hypertrophy in elite junior athletes: Relevance to differential diagnosis of athlete's heart and hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:1431-1436
6. Devereux RB, DahlÖf B, Gerdts E, Boman K, Nieminen MS,Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456-1462
7. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med. 1969;71:89-105
8. Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, DahlÖf B, Kjeldsen SE, Wachtell K. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension: The LIFE study. Am J Hypertens. 2012;25:1101-1109
9. Lindholm LH, Ibsen H, DahlÖf B, Devereux RB, Beevers G, de Faire U,Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J,Snapinn S; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:1004-1010
10. Olivetti G, Melissari M, Balbi T, Quaini F, Cigola E, Sonnenblick EH,Anversa P. Myocyte cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res. 1994;28:1199-1208
11. Boluyt MO, O'Neill L, Meredith AL, Bing OH, Brooks WW, Conrad CH, Crow MT, Lakatta EG. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: Marked upregulation of genes encoding extracellular matrix components. Circ Res. 1994;75:23-32
12. Lorell BH, Carabello BA. Left ventricular hypertrophy: Pathogenesis,detection, and prognosis. Circulation. 2000;102:470-479
13. Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J, Woods CE,Purcell NH, Catalucci D, Akasaka T, Bueno OF, Vlasuk GP, Kaliman P, Bodmer R, Smith LH, Ashley E, Mercola M, Brown JH, Ruiz-Lozano P. APJ acts as a dual receptor in cardiac hypertrophy. Nature. 2012;488:394-398
14. de Simone G, de Divitiis O. Extracellular matrix and left ventricular mechanics in overload hypertrophy. Adv Clin Path. 2002;6:3-10
15. Iwanaga Y, Aoyama T, Kihara Y, Onozawa Y, Yoneda T, Sasayama S. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol. 2002;39:1384-1391
16. Arnal JF, el Amrani AI, Chatellier G, Ménard J, Michel JB. Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension. 1993;22:380-387
17. Moreno H Jr, Metze K, Bento AC, Antunes E, Zatz R, de Nucci G. Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res Cardiol. 1996;91:248-255
18. Pechánová O, Bernátová I, Pelouch V, Babál P. L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiol Res. 1999;48:353-362
19. Xiao CY, Chen M, Zsengellér Z, Li H, Kiss L, Kollai M, Szabó C. Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J Pharmacol Exp Ther. 2005;312:891-898
20. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R,Hewett TE, Breit SN, Molkentin JD. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98:342-350
21. Yaniv Y, Juhaszova M, Wang S, Fishbein KW, Zorov DB, Sollott SJ. Analysis of mitochondrial 3D-deformation in cardiomyocytes during active contraction reveals passive structural anisotropy of orthogonal short axes. PLoS One. 2011;6:e21985
22. Thomas TA, Kuzman JA, Anderson BE, Andersen SM, Schlenker EH,Holder MS, Gerdes AM. Thyroid hormones induce unique and potentially beneficial changes in cardiac myocyte shape in hypertensive rats near heart failure. Am J Physiol Heart Circ Physiol. 2005;288:H2118-H2122
23. Boyett MR, Frampton JE, Kirby MS. The length, width and volume of isolated rat and ferret ventricular myocytes during twitch contractions and changes in osmotic strength. Exp Physiol. 1991;76:259-270
24. Sorenson AL, Tepper D, Sonnenblick EH, Robinson TF, Capasso JM. Size and shape of enzymatically isolated ventricular myocytes from rats and cardiomyopathic hamsters. Cardiovasc Res. 1985;19:793-799
25. Coelho-Filho OR, Mongeon FP, Mitchell R, Moreno H Jr, Nadruz W Jr,Kwong R, Jerosch-Herold M. Role of transcytolemmal water-exchange in magnetic resonance measurements of diffuse myocardial fibrosis in hypertensive heart disease. Circ Cardiovasc Imaging. 2013;6:134-141
26. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: Preliminary validation in humans. Circulation. 2010;122:138-144
27. Messroghli DR, Nordmeyer S, Buehrer M, Kozerke S, Dietrich T,Kaschina E, Becher PM, Hucko T, Berger F, Klein C, Kuehne T. Small animal Look-Locker inversion recovery (SALLI) for simultaneous generation of cardiac T1 maps and cine and inversion recovery-prepared images at high heart rates: Initial experience. Radiology. 2011;261:258-265
28. Deichmann R, Haase A. Quantification of T1 values by snapshot-flash NMR imaging. J Magn Reson. 1992;96:608-612
29. Landis CS, Li X, Telang FW, Molina PE, Palyka I, Vetek G, Springer CS Jr. Equilibrium transcytolemmal water-exchange kinetics in skeletal muscle in vivo. Magn Reson Med. 1999;42:467-478
30. Yankeelov TE, Rooney WD, Huang W, Dyke JP, Li X, Tudorica A,Lee JH, Koutcher JA, Springer CS Jr. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed. 2005;18:173-185
31. Landis CS, Li X, Telang FW, Coderre JA, Micca PL, Rooney WD, Latour LL, Vétek G, Pályka I, Springer CS Jr. Determination of the MRI contrast agent concentration time course in vivo following bolus injection: Effect of equilibrium transcytolemmal water exchange. Magn Reson Med. 2000;44:563-574
32. Jerosch-Herold M, Sheridan D, Kushner JD, Nauman DJ, Burgess D,Dutton D, Hershberger RE. Cardiac magnetic resonance contrast enhancement differentiates patients affected with familial dilated cardiomyopathy from asymptomatic relatives. J Cardiovasc Magn Reson. 2006;8:154-155
33. Schelbert EB, Testa SM, Meier CG, Ceyrolles WJ, Levenson JE, Blair AJ,Kellman P, Jones BL, Ludwig DR, Schwartzman D, Shroff SG, Wong TC. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: Slow infusion versus bolus. J Cardiovasc Magn Reson. 2011;13:16
34. Messroghli DR, Nordmeyer S, Dietrich T, Dirsch O, Kaschina E, Savvatis K, O h-Ici D, Klein C, Berger F, Kuehne T. Assessment of diffuse myocardial fibrosis in rats using small-animal Look-Locker inversion recovery T1 mapping. Circ Cardiovasc Imaging. 2011;4:636-640
35. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, Sibley CT, Chen MY, Bandettini WP, Arai AE. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J. 2012;33:1268-1278
36. Flett AS, Sado DM, Quarta G, Mirabel M, Pellerin D, Herrey AS,Hausenloy DJ, Ariti C, Yap J, Kolvekar S, Taylor AM, Moon JC. Diffuse myocardial fibrosis in severe aortic stenosis: An equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2012;13:819-826
37. Dorn GW 2nd, Robbins J, Sugden PH. Phenotyping hypertrophy: Eschew obfuscation. Circ Res. 2003;92:1171-1175
38. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR,Brown JH, Dorn GW 2nd. Enhanced Galphaq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A. 1998;95:10140-10145
39. Hein S, Arnon E, Kostin S, SchÖnburg M, Elsässer A, Polyakova V, Bauer EP, KlÖvekorn WP, Schaper J. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: Structural deterioration and compensatory mechanisms. Circulation. 2003;107:984-991
40. Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M. Left ventricular myocardial structure in aortic valve disease before,intermediate, and late after aortic valve replacement. Circulation. 1989;79:744-755
41. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-1549
42. Mohammed SF, Ohtani T, Korinek J, Lam CS, Larsen K, Simari RD,Valencik ML, Burnett JC Jr, Redfield MM. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via 'nongenomic effects.' Circulation. 2010;122:370-378
43. Shapiro BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC Jr, Redfield MM. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension. 2008;51:289-295
44. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional,and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089-2096
45. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Murphy NF, Conlon C,Patle A, Donnelly SC, McDonald K. Diagnosis of heart failure with preserved ejection fraction: Improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail. 2009;11:191-197
46. Post WS, Larson MG, Myers RH, Galderisi M, Levy D. Heritability of left ventricular mass: The Framingham Heart Study. Hypertension. 1997;30:1025-1028
47. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H,Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
48. Zhang Y, Poirier-Quinot M, Springer CS Jr, Balschi JA. Active transplasma membrane water cycling in yeast is revealed by NMR. Biophys J. 2011;101:2833-2842
49. Sawada K, Kawamura K. Architecture of myocardial cells in human cardiac ventricles with concentric and eccentric hypertrophy as demonstrated by quantitative scanning electron microscopy. Heart Vessels. 1991;6:129-142
50. Toischer K, Rokita AG, UnsÖld B, Zhu W, Kararigas G, Sossalla S, Reuter SP, Becker A, Teucher N, Seidler T, Grebe C, Preuss L, Gupta SN, Schmidt K, Lehnart SE, Krüger M, Linke WA, Backs J, Regitz-Zagrosek V, Schäfer K, Field LJ, Maier LS, Hasenfuss G. Differential cardiac remodeling in preload versus afterload. Circulation. 2010;122:993-1003